信必可都保对稳定期非囊性纤维化支气管扩张的疗效研究  

Therapeutic Effect of Budesonide-Formoterol Inhalation in Stable Period Non-cystic Fibrosis Bronchiectasis

作　　者：张菊英[1] 徐世成[1] 谭俊华[1] 吴龙飞[1] 刘春燕[1] 刘梦颖[2] 

机构地区：[1]川北医学院附属巴中医院门诊部,四川巴中636000 [2]第三军医大学临床医学系,重庆400038

出　　处：《现代生物医学进展》2013年第32期6319-6321,6350,共4页Progress in Modern Biomedicine

基　　金：国家自然科学基金项目(81171035)

摘　　要：目的:观察信必可都保(布地奈德-福莫特罗)对稳定期非囊性纤维化支气管扩张患者的临床疗效。方法:将42例稳定期非囊性支扩患者随机分为对照组(20例,常规服用氨茶碱0.1g,tid)、观察组(22例,在常规基础上加用信必可都保吸入剂,160μg/4.5μg,tid),疗程3个月,比较治疗前后两组肺功能指标(FEV1、FVC和PEF)及SGRQ评分。结果:对照组试验前后肺功能、SGRQ评分无显著改变(P>0.05);观察组肺功能无显著改变(P>0.05),SGRQ评分显著降低,差异有统计学意义(P<0.05)。结论:长期使用信必可都保吸入剂对稳定期非囊性纤维化支扩患者的生活质量有明显的改善作用,可有效控制气道炎症,但对改善肺功能无显著效果。Objective： To observe the therapeutic effect of budesonide-formoterol inhalation in patients with stable period NCFB. Methods： Forty-two patients with stable period bronchiectasis were randomly divided into control group （n=20, receiving aminophylline treatment, 0.1g, tid） and observation group （n=22, receiving budesonide-fomoterol treatment,160 Ixg/4.51xg, rid）. Pulmonary function and SGRQ score of the two group pre- and post-treatment were analyzed after 3 months. Results： Pulmonary function and SGRQ scores of the control group had no significant change after treatment （P〉0.05）; Pulmonary function of the observation group had no significant change after treatment （P〉0.05）. SGRQ score of the group significant reduced （P〈0.05）. Conclusion： Long-term inhalation ofbudes- onide-fo- moterol can significantly improve the quality of life in patients with stable period NCFB and can effectively control the airway inflamma- tion, but had no significant effect on improving pulmonary function.

关 键 词：支气管扩张 糖皮质激素 Β2受体激动剂 

分 类 号：R563[医药卫生—呼吸系统]